FDA redraws the development path for 17 generic peptide products

What happened

FDA published 17 revised draft product-specific guidances covering peptide products, including versions of semaglutide, liraglutide, glucagon, teriparatide, calcitonin and pegcetacoplan. The agency also withdrew a 2021 synthetic-peptide guidance that it said no longer reflected current scientific thinking.

What the record says

Product-specific guidance describes the studies and technical information FDA recommends for abbreviated new drug applications. For peptides, the revised approach addresses how a proposed generic can demonstrate sameness and control impurities without reducing the assessment to a single purity number.

What it does not mean

Draft guidance does not approve any pending generic application and does not alter the status of compounded versions. Each sponsor must still submit product-specific evidence that satisfies the statutory standard.

Why it matters

The move signals a more mature regulatory framework for complex peptide generics. That could influence competition and access, but the practical effect will depend on whether manufacturers can meet the analytical and clinical expectations in the final guidance.